Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIST-TEN
2021-001430-19Phase 2Active
- Sponsor
- Centre Léon Bérard
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of imatinib in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by Centre Léon Bérard. Primary endpoint: Progression-free rate at 6 months. Started Jun 2021; status: active.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2021-001430-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001430-19.